Background: There is a lack of consensus regarding the optimal technique for revision posterior cruciate ligament (PCL) reconstruction. Purpose: To evaluate midterm outcomes after revision PCL reconstruction using a single-bundle transtibial autograft. Study Design: Case series; Level of evidence, 4. Methods: We reviewed 17 patients who underwent revision PCL reconstruction performed in our medical center by a single surgeon from 2003 to 2016. The cohort included 12 male and 5 female patients with a mean age of 31.3 years (range, 17-48 years). All of the patients underwent single-bundle transtibial reconstruction using the same surgical technique and were reviewed at a minimum of 4 years postoperatively. Preoperative and postoperative posterior stress radiography was performed. The preoperative tibial slope and tibiofemoral angle were also measured. Preoperative and postoperative functional outcomes were evaluated using the International Knee Documentation Committee (IKDC) subjective and objective scores as well as the Lysholm score. Results: The most common factor that contributed to the failure of primary surgery was misplaced tunnels, especially on the femoral side. There were 2 patients who had grade 2 laxity preoperatively, and 15 patients had grade 3 laxity preoperatively. At the latest follow-up, all 17 patients had grade 1 laxity. On posterior stress radiography, posterior displacement improved from 10.8 ± 2.1 mm preoperatively to 2.9 ± 1.1 mm at the latest follow-up ( P < .001). The IKDC subjective score improved from 34.9 ± 6.8 preoperatively to 75.3 ± 15.7 postoperatively ( P < .001), and the Lysholm score improved from 38.1 ± 10.0 preoperatively to 88.5 ± 7.6 postoperatively ( P < .001). All patients reached the minimal clinically important difference (MCID) for the Lysholm score, and 94% reached the MCID for the IKDC subjective score, with 65% reaching the Patient Acceptable Symptom State. Conclusion: According to the findings of this study, arthroscopic revision PCL reconstruction with a single-bundle transtibial autograft offered satisfactory outcomes at midterm follow-up.
Background: The indications for Oxford unicompartmental knee arthroplasty (UKA) have been investigated for decades. The use of radiological decision aids for Oxford UKA is widespread; however, recent evidence suggests that there is a high false-negative rate. The 3-Tesla (3T) magnetic resonance imaging (MRI) system is more accurate than the 1.5T MRI system and may perform even better with Stage III and IV osteoarthritis. Here, we investigated the relationship between MRI findings and patient-reported outcomes following Oxford UKA. Methods: Medical records were reviewed retrospectively for 94 patients (101 knees) receiving Oxford UKA. All patients had a preoperative 3T MRI scan, which identified full-thickness cartilage loss. Evidence of bone-on-bone lesions from plain X-ray, bone marrow edema, and medial meniscus root tear was also recorded. Clinical outcomes were assessed using the Oxford knee score (OKS), Tegner Lysholm knee scoring system (TLKSS), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) six months postoperatively. Results: We reviewed 94 patients (101 knees, 30 in male patients and 71 in female patients) with full-thickness cartilage loss on 3T MRI. There were no significant differences in the TLKSS, OKS, or WOMAC between groups with and without bone-on-bone lesions, bone marrow edema, or medial meniscus root tear six months postsurgery. Conclusion: The 3T MRI system is an applicable radiographical decision aid for Oxford UKA patient selection. Full-thickness cartilage loss on 3T MRI is sufficient for identifying Oxford UKA beneficiaries, regardless of bone-on-bone lesions, bone marrow edema, or medial meniscus root tear
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.